Is cagrilintide a GLP-1?
No: a pharmacology paper describes cagrilintide (AM833) as a lipidated amylin analogue and a nonselective agonist of amylin and calcitonin receptors, which makes it an amylin drug rather than a GLP-1 drug.
Short answer
No: a pharmacology paper describes cagrilintide (AM833) as a lipidated amylin analogue and a nonselective agonist of amylin and calcitonin receptors, which makes it an amylin drug rather than a GLP-1 drug.[1]
In mice, cagrilintide's weight-lowering effect depended on the amylin receptors AMY1R and AMY3R.[2]
Compared with GLP-1 drugs
In the phase 2 trial, cagrilintide 4.5 mg produced a larger weight loss than liraglutide 3.0 mg: 10.8% against 9.0%.[3]
A meta-analysis of cagrilintide on its own found a mean body weight reduction of 6.08%.[4]
More questions on Cagrilintide
More on Cagrilintide
Sources
- 1AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.The Journal of pharmacology and experimental therapeutics · 2021PMID 33727283Accessed 2 Oct 2026
- 2Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine · 2025PMID 40609154Accessed 2 Oct 2026
- 3Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
- 4Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
Found an error? Report a correction.